Amgen slaps Sanofi, Regeneron with Dupixent lawsuit (Pharma)
Last month, Sanofi and Regeneron sued Amgen in a move to fend off a nasty patent court battle over their…More
Last month, Sanofi and Regeneron sued Amgen in a move to fend off a nasty patent court battle over their…More
Eli Lilly & Co.’s Olumiant rejection surprise Friday has one obvious beneficiary: Pfizer and its rival rheumatoid arthritis med, Xeljanz,…More
Anticipating an FDA approval later this year for a promising hereditary angioedema med from CSL, Shire has taken a preemptive…More
Bristol-Myers Squibb’s Opdivo dropped national TV ad spending in March after a bruising battle with a key competitor—Merck’s Keytruda—in February.…More
Roche’s checkpoint inhibitor Tecentriq, which won its initial approval as a treatment for bladder cancer, has now notched an approval…More
Even with a three-month extension, Eli Lilly was unable to quell FDA concerns about the safety risks of its highly…More
Endometriosis affects one in 10 women, but the fact that it’s common doesn’t mean it’s quickly diagnosed—in fact, it can…More
Boston subway riders—make that Boston “T” riders—passing through Kendall Square will be treated to local biopharma banter this month. To…More
A month after scoring a rare victory in a fight to defend the safety of its talcum powder, Johnson & Johnson is…More
Already struggling to meet initial expectations, Sanofi Pasteur’s dengue vaccine Dengvaxia will have to undergo phase 4 testing in Malaysia…More